A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 37 Pharma Execs Get 100 Million-Plus Yen in FY2021, Top 3 at Takeda: Securities Reports
July 1, 2022
-
REGULATORY Japan Begins TPOXX Clinical Research as It Braces for Monkeypox Outbreak
June 30, 2022
-
BUSINESS Wholesalers Bear Over 50 Billion Yen in Annual Costs Tied to Restricted Drug Supply: Crecon Estimate
June 29, 2022
-
BUSINESS Astellas/Sutro to Codevelop Next-Gen Immunostimulatory ADCs for Cold Tumors
June 29, 2022
-
BUSINESS Bimzelx as Driver, UCB Set to Derive Half of Global Sales from Immunology Biz
June 28, 2022
-
COMMENTARY Japan Should Accelerate Debate on Legalizing Cannabis-Derived Drugs for Refractory Epilepsies
June 27, 2022
-
ORGANIZATION Kichiro Matsumoto Elected as New Chief of Japan Medical Association
June 27, 2022
-
BUSINESS 25 Japan Drug Makers Log Combined 10.7% Growth in FY2021, 12 See Two-Digit Jumps: Tally
June 24, 2022
-
REGULATORY Japan Shelves Decision on Shionogi’s COVID Pill with Experts at Odds, Another Session Likely Next Month
June 23, 2022
-
BUSINESS Biosimilars Likely to Gain Further Impetus from Govt Push; Forteo/Enbrel Hit 40% Share, Herceptin 50%-Plus
June 22, 2022
-
REGULATORY Kazuhiro Oshima Tapped as Vice Health Minister, Katsufumi Jo as First Councilor for Pharma Industry Promotion
June 22, 2022
-
REGULATORY Japan Approves Janssen’s COVID Jab, Sanofi’s Sutimlimab, Olumiant’s Alopecia Use and More
June 21, 2022
-
BUSINESS Astellas Workforce Down by More than 700: Securities Report
June 21, 2022
-
BUSINESS PeptiDream Set to Develop Peptide-RI Conjugates for Refractory Cancers, Eyes No. 1 Spot in Radiotherapy
June 20, 2022
-
REGULATORY As Election Campaigns Begin, Parties Pitch Policies to Bolster Drug Development, Supply Chains
June 17, 2022
-
BUSINESS Patent Rows Don’t Stop Generic Players; Single Entries, AG Non-Launches Seen in June Listing
June 17, 2022
-
REGULATORY Feburic, Samsca, and More Face First Generics in June Listing, No Xarelto/Eylea AGs
June 16, 2022
-
REGULATORY Kishida Officially Unveils Plan to Form Pandemic Response Agency, Japan CDC
June 16, 2022
-
REGULATORY Shionogi’s COVID Pill Up for PAFSC Review for 1st Emergency Approval
June 16, 2022
-
REGULATORY Japan to Create Expert Panel to Ponder Drug Distribution and Pricing: Kanmin Taiwa
June 15, 2022
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…